newsfilter
← Latest News
Business Wire·

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results

- Phase 2 SOLSTICE data presented at the EASL Congress showed that elebsiran and tobevibart achieved undetectable HDV RNA in 88% of participants with chronic hepatitis delta (CHD) at Week 96 of treatment - Topline